Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Exclusion Criteria

• •1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients;
• •2. Squamous cancer, small-cell lung cancer;
• •3. Symptomatic central nervous system (CNS) metastases
• •4. Hypertension and couldn't be controlled with medicine;
• •5. Coagulation disorders;
• •6. Clinical significant bleeding in 3 months prior dosing;
• •7. Had surgery in four weeks prior dosing;
• •8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction;
• •9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months prior dosing;
• •10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours;
• •11. Active infection and need antimicrobial treatments;
• •12. History of psychiatric substance abuse;
• •13. Take any clinical trial drugs within four weeks prior dosing;
• •14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and CYP2D6;
• •15. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;
• •16. Addicted to alcohol and tobacco;
• •17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and alcohol in 48 hours prior dosing;